An international consensus approach to the management of atypical hemolytic uremic syndrome in children (Q33421861)

26 July 2017

1 reference

title

An international consensus approach to the management of atypical hemolytic uremic syndrome in children (English)

1 reference

atypical hemolytic uremic syndrome

26 July 2017

1 reference

10

Diana Karpman

1 reference

Véronique Frémeaux-Bacchi

26 July 2017

21

object named as

Véronique Frémeaux-Bacchi

1 reference

26 July 2017

3

Gema Ariceta

1 reference

26 July 2017

9

Sally Johnson

1 reference

26 July 2017

14

Christoph Licht

1 reference

26 July 2017

8

Francesco Emma

1 reference

26 July 2017

Chantal Loirat

1

1 reference

26 July 2017

Fadi Fakhouri

2

1 reference

26 July 2017

Nesrin Besbas

4

1 reference

26 July 2017

Martin Bitzan

5

1 reference

26 July 2017

Anna Bjerre

6

1 reference

26 July 2017

Rosanna Coppo

7

1 reference

26 July 2017

Daniel Landau

11

1 reference

26 July 2017

Craig B Langman

12

1 reference

26 July 2017

Anne-Laure Lapeyraque

13

1 reference

26 July 2017

Carla Nester

15

1 reference

26 July 2017

Carmine Pecoraro

16

1 reference

26 July 2017

Magdalena Riedl

17

1 reference

26 July 2017

Nicole C A J van de Kar

18

1 reference

26 July 2017

Johan Van de Walle

19

1 reference

26 July 2017

Marina Vivarelli

20

1 reference

26 July 2017

HUS International

22

1 reference

26 July 2017

11 April 2015

1 reference

26 July 2017

1 reference

26 July 2017

31

1 reference

26 July 2017

15-39

1 reference

26 July 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1007/s00467-015-3076-8

26 July 2017

0 references

cites work

Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Complement therapy in atypical haemolytic uraemic syndrome (aHUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Complement Mutation-AssociatedDe NovoThrombotic Microangiopathy Following Kidney Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Update on Streptococcus pneumoniae associated hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Paradigm shift of childhood thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Thrombotic thrombocytopenic purpura in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Inherited thrombotic thrombocytopenic purpura in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Surveillance of hemolytic uremic syndrome in children less than 15 years of age, a system to monitor O157 and non-O157 Shiga toxin-producing Escherichia coli infections in France, 1996-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Long-term outcomes of Shiga toxin hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Hemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Neonatal atypical hemolytic uremic syndrome due to methylmalonic aciduria and homocystinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Combined pulmonary hypertension and renal thrombotic microangiopathy in cobalamin C deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Clinical presentation and outcome in a series of 88 patients with the cblC defect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Three new cases of late-onset cblC defect and review of the literature illustrating when to consider inborn errors of metabolism beyond infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Does dysregulated complement activation contribute to haemolytic uraemic syndrome secondary to Streptococcus pneumoniae?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Interaction of Shiga toxin 2 with complement regulators of the factor H protein family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Late-onset thrombocytic microangiopathy caused by cblC disease: association with a factor H mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

CD46-associated atypical hemolytic uremic syndrome with uncommon course caused by cblC deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Management of hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Anti-factor H autoantibody-associated hemolytic uremic syndrome: the earlier diagnosed and treated, the better

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Complement factor H-antibody-associated hemolytic uremic syndrome: pathogenesis, clinical presentation, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Peripheral gangrene in children with atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Phenotypic expansion of DGKE-associated diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Complement mutations in diacylglycerol kinase-ε-associated atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Determining the population frequency of the CFHR3/CFHR1 deletion at 1q32.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

21 January 2018

DGKE and atypical HUS.

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Dynamics of complement activation in aHUS and how to monitor eculizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Standardisation of the factor H autoantibody assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Outcomes of renal transplant in patients with anti-complement factor H antibody-associated hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Post-transplant recurrence of atypical hemolytic uremic syndrome in a patient with thrombomodulin mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Liver-kidney transplantation to cure atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Preservation of renal function in atypical hemolytic uremic syndrome by eculizumab: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Eculizumab for the treatment of atypical hemolytic uremic syndrome: case report and revision of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Eculizumab as first-line therapy for atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Eculizumab in neonatal hemolytic uremic syndrome with homozygous factor H deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Clinical grand rounds: atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Successful long-term treatment of TMA with eculizumab in a transplanted patient with atypical hemolytic uremic syndrome due to MCP mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Anti-C5 as prophylactic therapy in atypical hemolytic uremic syndrome in living-related kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Complement. First of two parts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Immunogenicity of meningococcus C vaccination in a patient with atypical hemolytic uremic syndrome (aHUS) on eculizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Meningococcal sepsis complicating eculizumab treatment despite prior vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Successful treatment of DEAP-HUS with eculizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Atypical HUS due to factor H antibodies in an adult patient successfully treated with eculizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Complement activation in thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

STEC-HUS, atypical HUS and TTP are all diseases of complement activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: additional data and clinical follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Cryptic activity of atypical hemolytic uremic syndrome and eculizumab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Skin involvement in atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Profound neurological injury in a patient with atypical hemolytic uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Non-atheromatous arterial stenoses in atypical haemolytic uraemic syndrome associated with complement dysregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Prevention of large-vessel stenoses in atypical hemolytic uremic syndrome associated with complement dysregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Macrovascular involvement in a child with atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Report from the Editorial Office

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Vitamin C and functional iron deficiency anemia in hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Cardiovascular complications in atypical haemolytic uraemic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Genetic variants in C5 and poor response to eculizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Complement inhibitor eculizumab in atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Changing strategies for organ transplantation in atypical haemolytic uraemic syndrome: a tertiary case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

Anesthetic management of living donor liver transplantation for complement factor H deficiency hemolytic uremic syndrome: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-015-3076-8

An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document

21 January 2018

1 reference

12 December 2020

Eculizumab in atypical haemolytic-uraemic syndrome allows cessation of plasma exchange and dialysis

1 reference

12 December 2020

Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura

1 reference

12 December 2020

Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies

1 reference

12 December 2020

Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated?

1 reference

12 December 2020

Atypical haemolytic-uraemic syndrome due to heterozygous mutations of CFH/CFHR1-3 and complement factor H 479.

1 reference

12 December 2020

Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome

1 reference

12 December 2020

Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission

1 reference

12 December 2020

Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome.

1 reference

12 December 2020

[Eculizumab: effectiveness of a shortened dosing schedule in the treatment of atypical haemolytic uremic syndrome of unknown origin]

1 reference

12 December 2020

Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome

1 reference

12 December 2020

Liver-kidney transplantation to cure atypical HUS: still an option post-eculizumab?

1 reference

12 December 2020

Successful discontinuation of eculizumab therapy in a patient with aHUS

1 reference

12 December 2020

Renal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysis

1 reference

12 December 2020

Evaluation of a commercial assay for ADAMTS13 activity measurement

1 reference

12 December 2020

Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft

1 reference

12 December 2020

Living kidney transplantation in adult patients with atypical haemolytic uraemic syndrome

1 reference

12 December 2020

Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura

1 reference

12 December 2020

10.1007/S00467-015-3076-8

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference